Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BPI-572270 in RAS-mutant advanced solid tumors
CTR20260302Phase 2Active
- Sponsor
- Jingyao Biotech
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of BPI-572270 in pancreatic adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), colorectal cancer (CRC), Nonhematologic neoplasms, sponsored by Jingyao Biotech. Started Feb 2026; status: active.
02
Drugs
BPI-572270
03
Conditions
pancreatic adenocarcinoma (PDAC)non-small cell lung cancer (NSCLC)colorectal cancer (CRC)Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20260302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260302.